Characteristics | Patients with hyperuricemia | Patients without hyperuricemia | p value |
---|---|---|---|
(n = 147) | (n = 487) | ||
Serum uric acid 8.9 (7.1–8.9) mg/dl | Serum uric acid 5.0 (4.1–5.7) mg/dl | ||
Demographic characteristics | |||
Age (year) | 65.6 ± 15.1 | 62.0 ± 13.1 | 0.003 |
Male | 114 (77.6) | 389 (79.9) | 0.542 |
Hypertension | 97 (66.0) | 265 (54.4) | 0.013 |
Diabetes mellitus | 27 (18.4) | 87 (17.9) | 0.889 |
Dyslipidemia | 4 (2.7) | 12 (2.5) | 0.772 |
Current smoking | 71 (48.3) | 278 (57.1) | 0.061 |
Previous myocardial infarction | 6 (4.1) | 11 (2.3) | 0.246 |
Previous revascularization | 5 (3.4) | 19 (3.9) | 0.781 |
Previous stroke | 15 (10.2) | 27 (5.5) | 0.046 |
Clinical presentation | |||
SVT/VF before PPCI | 8 (5.4) | 19 (3.9) | 0.417 |
Cardiogenic shock at admission | 42 (28.6) | 69 (14.2) | 0.000 |
hsCRP (mg/L) | 8.0 (3.6–19.8) | 5.0 (2.0–16.0) | 0.002 |
Serum potassium (mmol/L) | 4.0 ± 0.4 | 4.0 ± 0.5 | 0.220 |
Serum natrium (mmol/L) | 139.5 ± 4.1 | 138.6 ± 3.3 | 0.016 |
Serum chlorinum (mmol/L) | 105.5 ± 7.7 | 105.1 ± 4.00 | 0.452 |
eGFRMDRD (ml/min/1.73m2) | 57.1 ± 20.2 | 80.2 ± 22.2 | 0.000 |
Fasting glucose (mmol/L) | 8.2 ± 3.5 | 7.1 ± 2.8 | 0.001 |
HbA1c (%) | 6.4 ± 1.5 | 2.7 ± 1.7 | 0.540 |
Peak troponin I (ng/ml) | 67.6 (22.8–153.2) | 42.8 (17.9–87.0) | 0.009 |
BNP (pg/ml) | 1149.5 (302.0–3376.5) | 709.5 (254.3–1698.8) | 0.003 |
Triglycerides (mmol/L) | 1.7 ± 1.2 | 1.5 ± 1.1 | 0.056 |
Total cholesterol (mmol/L) | 4.3 ± 1.3 | 4.2 ± 1.1 | 0.336 |
HDL-C (mmol/L) | 1.0 ± 0.3 | 1.0 ± 0.3 | 0.133 |
LDL-C (mmol/L) | 2.9 ± 1.0 | 2.8 ± 0.8 | 0.628 |
LVEF (%) | 57.5 ± 11.4 | 60.1 ± 9.1 | 0.018 |
Medical treatment after PPCI | |||
Aspirin | 146 (99.3) | 486 (99.8) | 0.410 |
Clopidogrel | 135 (91.8) | 462 (94.9) | 0.170 |
Ticagrelor | 11 (7.5) | 25 (5.1) | 0.281 |
Beta-blockers | 91 (61.9) | 328 (67.4) | 0.222 |
Statin | 138 (93.9) | 485 (99.6) | 0.000 |
ACEI/ARB | 98 (66.7) | 333 (68.4) | 0.697 |
Aminodarone | 21 (14.3) | 48 (9.9) | 0.131 |
Lidocaine | 14 (9.5) | 28 (5.7) | 0.107 |